MCRB stock forecast
Our latest prediction for Seres Therapeutics, Inc.'s stock price was made on the June 18, 2019 when the stock price was at 2.61$.
In the short term (2weeks), MCRB's stock price should outperform the market by 7.19%. During that period the price should oscillate between -8.82% and +22.46%.
In the medium term (3months), MCRB's stock price should outperform the market by 7.31%. During that period the price should oscillate between -20.85% and +54.80%.Get email alerts
About Seres Therapeutics, Inc.
Seres Therapeutics, Inc. operates a microbiome therapeutics platform company, which engages in the development of biological drugs. The firm creates medicines using live bacteria to treat diseases resulting from functional deficiencies in the microbiome, a condition known as dysbiosis. It focuses on implementing microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. The company was founded by Geoffrey von Maltzahn, David A. Berry and Noubar B. Afeyan on October 18, 2010 and is headquartered in Cambridge, MA.
At the moment the company generates 32M USD in revenues.
On its last earning announcement, the company reported a loss of -2.33$ per share.
The book value per share is -0.32$
Three months stock forecastJune 18, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|